WASHINGTON, D.C. (Friday, August 20, 2010) - Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on the Public Health Emergency Medical Countermeasures Enterprise Review released yesterday by Health and Human Services (HHS) Secretary Kathleen Sebelius:
“BIO applauds HHS for the release of their new vision statement and strategy document resulting from the assessment of the current public health emergency medical countermeasures enterprise. We are pleased that the Administration is highlighting this critical component of national security and believe this document is an important first step in focusing on the key issue of the development and procurement of medical countermeasures. We appreciate that the HHS recommendations, such as investing in FDA regulatory science and shifting to a multi-year budget approach, seek to address the challenges facing the biotechnology companies that are dedicated to helping the nation respond to public health threats.
“We look forward to working with HHS and other key government and academic stakeholders to implement these initiatives and other ideas that will help to sustain and further develop the biodefense enterprise.
“We also look forward to participating in further discussions regarding other important elements of preparedness such as investments in detection and surveillance as well as distribution mechanisms. We concur with HHS that the rapid detection of health threats and timely distribution of safe and effective medical countermeasures are pivotal to our nation’s ability to respond to any biological threats.”
Upcoming BIO Events
September 21 - 22, 2010
BIO’s Livestock Biotechnology Summit
September 28-30, 2010,
Sioux Falls, SD
BIO Investor Forum
October 5-6, 2010
San Francisco, CA
BIO Intellectual Property Counsels Committee Fall Conference and Committee Meeting
October 18-20, 2010
Advanced Business Development Course
November 12-14, 2010
BIO-Europe International Partnering Conference
November 15-17, 2010
Pacific Rim Summit on Industrial Biotechnology and Bioenergy
December 11-14, 2010
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtech Now, an online portal and monthly newsletter chronicling “innovations transforming our world.” Subscribe to BIOtech Now.